日本的胰癌症治療市場:各癌症類型，各治療類型，各終端用戶，各地區，機會，預測，2019年～2033年

日本胰臟癌治療市場規模預計將從 2025 年的 1.252 億美元增長到 2033 年的 3.2377 億美元，預測期內（2026-2033 年）的複合年增長率為 12.61%。醫療保健技術的快速進步、老齡化人口的增長以及國內胰腺癌患病率的上升是推動市場發展的一些因素。國內領先的製藥公司越來越注重開發和引進新療法，以應對日益加重的慢性病負擔。根據世界癌症研究基金會估計，2022年日本將通報47,627例胰臟癌新發病例。

製藥公司和研究機構之間日益增多的合作正在刺激免疫療法和基因療法等治療方法的創新。此外，日本擁有高度先進的醫療設施，可以為病患提供優質的醫療服務。同時，政府加強醫療保健基礎設施和增加癌症研究資金的措施進一步促進了市場的成長和擴張。這些努力正在改善獲得先進治療和早期癌症檢測技術的機會，使醫療保健專業人員能夠應對胰臟癌的侵襲性。

本報告提供日本的胰癌症治療市場相關調查，提供市場概要，以及各癌症類型，各治療類型，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 日本胰癌症治療市場預測(2019年～2033年)

• 市場規模分析與預測
• 市場佔有率分析與預測
• 2025年市場地圖分析
  • 各癌症類型
  • 各治療類型
  • 各終端用戶
  • 各地區

第5章 需求供給分析

第6章 價值鏈分析

第7章 波特的五力分析

第8章 大環境分析

第9章 價格分析

第10章 市場動態

• 市場促進因素
• 市場課題

第11章 市場趨勢與發展

第12章 法規情形

第13章 臨床試驗

第14章 案例研究

第15章 競爭情形

• 前五名市場領導的競爭矩陣
• 前五名參與企業的SWOT分析
• 前10名市場主要企業的形勢
  • AstraZeneca K.K.
  • Pfizer Japan Inc.
  • Teva Takeda Yakuhin Ltd.
  • Novartis Pharma K.K.
  • Sanofi K.K.
  • GlaxoSmithKline K.K.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb K.K.
  • Eli Lilly Japan K.K.
  • Eisai Co., Ltd.

第16章 策略性建議

第17章 關於調查公司·免責聲明

Japan pancreatic cancer treatment market is projected to witness a CAGR of 12.61% during the forecast period FY2026-FY2033, growing from USD 125.20 million in FY2025 to USD 323.77 million in FY2033. The rapid advancements in healthcare technologies, expansion of the aging population, and increasing prevalence of pancreatic cancer in the country are some of the drivers of the market. Leading pharmaceutical companies in the country are increasingly focusing on developing and introducing novel therapies to combat the increasing burden of the chronic condition. According to the estimates of the World Cancer Research Fund, 47,627 new cases of pancreatic cancer were reported in Japan in 2022.

Increasing collaborations between pharmaceutical companies and research institutions are fostering innovation in treatment modalities, including immunotherapy and gene therapy. Additionally, the availability of highly sophisticated healthcare facilities in the country ensures the provision of high-quality care for the patient population. Meanwhile, government initiatives to enhance healthcare infrastructure and boost funding for cancer research are further supporting the market's growth and expansion as these efforts improve access to advanced therapies and early cancer detection technologies, allowing the medical professionals to address the aggressive nature of pancreatic cancer.

Increasing Research Activities Support Market Expansion

Rising research efforts that focus on developing novel therapies such as targeted agents, immunotherapies, and gene therapies are providing lucrative growth opportunities for the market. Japanese research institutions are collaborating with other research institutions across the globe to develop new therapies that aid in combating the growing threat of pancreatic cancer. For instance, recently Israeli and Japanese researchers have made a significant breakthrough in cancer treatment by developing a highly targeted inhibitor for the Matrix Metallopeptidase 7 (MMP7) enzyme. This enzyme plays a critical role in cancer growth and spread, particularly in aggressive forms like pancreatic cancer. The collaborative effort involved the University of Tokyo and the Hebrew University of Jerusalem, the Weizmann Institute of Science. Such collaborative activities are expected to bolster the availability of novel therapeutic solutions for pancreatic cancer and provide lucrative growth opportunities for the market.

Technological Innovations in Testing Methods Boost Market Growth

Technological innovations in testing methods are positively influencing the market's expansion by enabling personalized care and early disease detection. Such innovations also enhance treatment outcomes by facilitating timely interventions, which are crucial for managing pancreatic cancer's aggressive nature. Early detection also supports the use of targeted therapies and precision medicine, optimizing treatment efficacy and minimizing side effects. Thus, leading research institutions across the country are focusing on developing new methods for testing pancreatic cancer. For instance, in February 2025, researchers from Osaka University announced that they have developed a method for testing pancreatic cancer with DNA collected during gastric examinations from a modified catheter. This technique streamlines the early detection of pancreatic cancer, which is usually challenging, by employing modified catheters for gathering samples. The technique also improves early diagnosis rates by analyzing pancreatic juice flowing into duodenum.

Additionally, in September 2024, researchers from Kyoto University announced that the university along with Arkray Inc. have developed an innovative artificial intelligence-based method to detect early-stage pancreatic cancer. The team utilized microRNAs, small RNA fragments that regulate genetic functions, alongside conventional tumor markers to create a diagnostic model. Such breakthroughs could significantly improve rate of detection, providing better survival outcomes for the patients and propel the market's demand.

Exocrine Cancer Accounts for Significant Share of the Market

Due to the high prevalence and aggressive nature, exocrine pancreatic cancer dominates the market. This cancer is highly invasive and is diagnosed at later stages due to lack of availability of effective screening tools and early symptoms. Additionally, the expansion of the aging population in the country further increases the prevalence of the condition. As per the estimates of the World Economic Forum, more than 1 in 10 people are 80 or older in Japan.

Meanwhile, evolving lifestyle is also increasing the prevalence of exocrine pancreatic cancer in Japan. Rising popularity of smoking and consumption of animal fat in the country are significantly contributing to the growing cases. In order to combat the growing threat of the condition, major pharma corporations and research institutions are focusing on developing innovative therapies, improving survival rates and driving the growth of the market.

Hospitals Hold Major Market Share

Due to the central role hospitals play in providing comprehensive care for complex diseases and disorders such as cancer, they hold a significant share in the market. Hospitals are the primary sites in Japan for administration of radiation therapy and chemotherapy and for performing surgeries, essential for treating pancreatic cancer. Hospitals such as Cancer Institute Hospital of JFCR in Tokyo are leading sites for treating pancreatic cancer as they adopt advanced therapies such as immunotherapies and targeted treatment solutions. Meanwhile, government backed initiatives and investments in infrastructure of hospitals in Japan to ensure the provision of high-quality care for the patient population are also making hospitals the preferred setting for management of pancreatic cancer.

Future Market Scenario (FY2026 - FY2033F)

The market is expected to witness significant growth over the forecast period due to increasing innovations in immunotherapy, precision medicine, and targeted therapies. Meanwhile, growing focus on expansion of early pancreatic cancer detection technologies with the help of novel diagnostic techniques and artificial intelligence powered cancer detection tools are further expected to bolster the market's demand in Japan.

With major pharmaceutical companies in Japan investing heavily in next-generation cancer treatments, the number of treatment solutions available for the patient population are expected to increase significantly in the coming years. As the country's regulatory framework evolves and more cost-effective treatments emerge, the quality of life of the patients will improve along with the survival rates.

Key Players Landscape and Outlook

Startups across Japan are supporting the development of new tools that harness artificial intelligence for treating and diagnosing pancreatic cancer among other diseases. Companies are focusing on high-intensity focused ultrasound (HIFU) as the HIFU waves do not damage heathy cells they pass through and can be focused on a small region inside the body. Meanwhile, conventional radiotherapy damages both healthy cells and cancer cells that the radiation passes through. Thus, clinicians in the country are now working on ensuring that HIFU becomes the standard treatment for pancreatic cancer.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan Pancreatic Cancer Treatment Market Outlook, FY2019-FY2033F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Cancer Type
    • 4.2.1.1. Endocrine Pancreatic Cancer
    • 4.2.1.2. Exocrine Pancreatic Cancer
  • 4.2.2. By Treatment Type
    • 4.2.2.1. Chemotherapy
    • 4.2.2.2. Radiation Therapy
    • 4.2.2.3. Targeted Therapy
    • 4.2.2.4. Immunotherapy
    • 4.2.2.5. Hormone Therapy
    • 4.2.2.6. Others
  • 4.2.3. By End-user
    • 4.2.3.1. Hospitals
    • 4.2.3.2. Clinics
    • 4.2.3.3. Cancer Care Centers
    • 4.2.3.4. Others
  • 4.2.4. By Region
    • 4.2.4.1. North [Hokkaido and Tohoku]
    • 4.2.4.2. Central [Kanto and Chubu]
    • 4.2.4.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 4.3. Market Map Analysis, FY2025
  • 4.3.1. By Cancer Type
  • 4.3.2. By Treatment Type
  • 4.3.3. By End-user
  • 4.3.4. By Region

5. Demand Supply Analysis

6. Value Chain Analysis

7. Porter's Five Forces Analysis

8. PESTLE Analysis

9. Pricing Analysis

10. Market Dynamics

• 10.1. Market Drivers
• 10.2. Market Challenges

11. Market Trends and Developments

12. Regulatory Landscape

13. Clinical Trials

14. Case Studies

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. AstraZeneca K.K.
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 15.3.2. Pfizer Japan Inc.
  • 15.3.3. Teva Takeda Yakuhin Ltd.
  • 15.3.4. Novartis Pharma K.K.
  • 15.3.5. Sanofi K.K.
  • 15.3.6. GlaxoSmithKline K.K.
  • 15.3.7. Merck & Co., Inc.
  • 15.3.8. Bristol-Myers Squibb K.K.
  • 15.3.9. Eli Lilly Japan K.K.
  • 15.3.10. Eisai Co., Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Pancreatic Cancer Treatment Market, By Value, In USD Million, FY2019-FY2033F
• Figure 2. Japan Pancreatic Cancer Treatment Market Share (%), By Cancer Type, FY2019-FY2033F
• Figure 3. Japan Pancreatic Cancer Treatment Market Share (%), By Treatment Type, FY2019-FY2033F
• Figure 4. Japan Pancreatic Cancer Treatment Market Share (%), By End-user, FY2019-FY2033F
• Figure 5. Japan Pancreatic Cancer Treatment Market Share (%), By Region, FY2019-FY2033F
• Figure 6. By Cancer Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 7. By Treatment Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 8. By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 9. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2025